CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci193745 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Yi Bao und 27 weiteren Autor:innen. Beteiligte Einrichtung: Michigan Center for Translational Pathology. Hauptthemen laut MEDLINE: Membrane Proteins, Cyclin-Dependent Kinases, Neoplasm Proteins, Prostatic Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Chinese Academy of Sciences.
Abstract (Originalsprache)
Inactivation of cyclin-dependent kinase 12 (CDK12) defines an immunogenic molecular subtype of prostate cancer characterized by genomic instability and increased intratumoral T cell infiltration. This study revealed that genetic or pharmacologic inactivation of CDK12 and its paralog CDK13 robustly activates stimulator of interferon genes (STING) signaling across multiple cancer types. Clinical cohort analysis showed that reduced CDK12/13 expression correlates with improved survival and response to immune checkpoint blockade (ICB). Mechanistically, CDK12/13 depletion or targeted degradation induced cytosolic nucleic acid release, triggering STING pathway activation. CDK12/13 degradation delayed tumor growth and synergized with anti–PD-1 therapy in syngeneic tumor models, enhancing STING activity and promoting CD8 + T cell infiltration and activation within tumors. Notably, the antitumor effects of this combination required STING signaling and functional CD8 + T cells. These findings establish STING activation as the key driver of T cell infiltration and the immune-hot tumor microenvironment in CDK12-mutant cancers, suggesting that dual CDK12/13 inhibitors and degraders activate antitumor immunity and potentiate responses to immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Michigan Center for Translational Pathology.
- Department of Pathology, and.
- Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
- State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Developme…
- Department of Surgery.
Förderung
- NCI NIH HHS
- National Cancer Institute
- Chinese Academy of Sciences
Zitieren
APA
Bao, Y., Chang, Y., Tien, J. C., Cruz, G., Yang, F., Mannan, R., Mahapatra, S., Paturu, R., Cao, X., Su, F., Wang, R., Zhang, Y., Gondal, M., Choi, J. E., Gurkan, J. K., Miner, S. J., Robinson, D. R., Wu, Y. M., Zhou, L., …, & Chinnaiyan, A. M. (2025). CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models. Journal of Clinical Investigation. https://doi.org/10.1172/jci193745
Vancouver
Bao Y, Chang Y, Tien JC, Cruz G, Yang F, Mannan R, et al. CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models. Journal of Clinical Investigation. 2025. doi:10.1172/jci193745
BibTeX
@article{Bao2025,
author = {Bao, Yi and Chang, Yu and Tien, Jean Ching-Yi and Cruz, Gabriel and Yang, Fan and Mannan, Rahul and Mahapatra, Somnath and Paturu, Radha and Cao, Xuhong and Su, Fengyun and Wang, Rui and Zhang, Yuping and Gondal, Mahnoor and Choi, Jae Eun and Gurkan, Jonathan K and Miner, Stephanie J and Robinson, Dan R and Wu, Yi-Mi and Zhou, Licheng and Wang, Zhen and Kryczek, Ilona and Wang, Xiaoju and Cieslik, Marcin and Qiao, Yuanyuan and Tsodikov, Alexander and Zou, Weiping and Ding, Ke and Chinnaiyan, Arul M},
title = {CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci193745}
}
EUVIMED